A report in the Daily Telegraph quoted Dr Winter stating that in respect of the VAT increase that "No one doubts that recombinant Factor VIII is the best treatment. It is the safest and it is the future." Read more about A report in the Daily Telegraph quoted Dr Winter stating that in respect of the VAT increase that "No one doubts that recombinant Factor VIII is the best treatment. It is the safest and it is the future."
The Haemophilia Society wrote to the Chancellor of the Exchequer, Kenneth Clarke, and asked him to reverse the VAT decision regarding recombinant product in the forthcoming budget. It described it as "vital" that this "new, safer product should be available, at least to young children." Read more about The Haemophilia Society wrote to the Chancellor of the Exchequer, Kenneth Clarke, and asked him to reverse the VAT decision regarding recombinant product in the forthcoming budget. It described it as "vital" that this "new, safer product should be available, at least to young children."
Dr Geoffrey Savidge, wrote to the Secretary of State for Health, Stephen Dorrell, stating that recombinant Factor 8 "represents the safest product available to patients" and sought reassurances that it would remain affordable. Read more about Dr Geoffrey Savidge, wrote to the Secretary of State for Health, Stephen Dorrell, stating that recombinant Factor 8 "represents the safest product available to patients" and sought reassurances that it would remain affordable.
Dr Christine Lee and Dr Brian Colvin wrote to the Secretary of State for Health, Stephen Dorrell, to argue the case for payment of the costs of treatment with recombinant Factor 8 concentrate. Read more about Dr Christine Lee and Dr Brian Colvin wrote to the Secretary of State for Health, Stephen Dorrell, to argue the case for payment of the costs of treatment with recombinant Factor 8 concentrate.
Professors Edward Tuddenham and Mike Laffan wrote in the British Medical Journal that: "Recombinant factor VIII is therefore the treatment of choice, given its freedom from viruses derived from plasma..." Read more about Professors Edward Tuddenham and Mike Laffan wrote in the British Medical Journal that: "Recombinant factor VIII is therefore the treatment of choice, given its freedom from viruses derived from plasma..."
The first recombinant factor product was Factor 8. The recombinant Factor 8 within the product, which was the only active ingredient, constituted less than 1% by volume. Read more about The first recombinant factor product was Factor 8. The recombinant Factor 8 within the product, which was the only active ingredient, constituted less than 1% by volume.
Work was ongoing to review the funding of palliative and end of life care services across Wales. Read more about Work was ongoing to review the funding of palliative and end of life care services across Wales.
James Sanderson, director of Community Health and Personalised Care at NHS England, explained palliative and end of life care is delivered by, and across a range of, local and national statutory and voluntary organisations. Read more about James Sanderson, director of Community Health and Personalised Care at NHS England, explained palliative and end of life care is delivered by, and across a range of, local and national statutory and voluntary organisations.
Caroline Leonard, director of surgery and specialist services at the Belfast Health and Social Care Trust, highlighted that delivering palliative care well is not necessarily easy. Read more about Caroline Leonard, director of surgery and specialist services at the Belfast Health and Social Care Trust, highlighted that delivering palliative care well is not necessarily easy.
When asked about palliative care in Scotland, Professor John Dillon stated implementation of standards of care which are being formulated by professional societies will be via local bids for funding services, unless there is a directive government policy. Read more about When asked about palliative care in Scotland, Professor John Dillon stated implementation of standards of care which are being formulated by professional societies will be via local bids for funding services, unless there is a directive government policy.